. But, according to Brook Baker, a professor of law at Northeastern University who has tracked the negotiations over the drug, the price of a course of treatment could fall below $10 as competition increases among manufacturers and production scale grows.
“We had a responsibility,” she added. “You could not have a capsule and not be able to find a way to get it across the world.”Molnupiravir has yet to receive approval from either U.S. or European regulators. Merck applied to the U.S. Food and Drug Agency for emergency use authorization this month and the European Medicines Agency recently began a rolling review of the drug.But experts say that it has huge potential to fight the pandemic.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: